Literature DB >> 12511558

A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3.

Lalitha Subramanian1, Mark D Benson, Jorge A Iñiguez-Lluhí.   

Abstract

One of the most common forms of functional interaction among transcription factors is the more than additive effect at promoters harboring multiple copies of a response element. The mechanisms that enable or control synergy at such compound response elements are poorly understood. We recently defined a common motif within the negative regulatory regions of multiple factors that operates by regulating their transcriptional synergy. We have identified such a synergy control (SC) motif embedded within the "attenuator domain" of CCAAT/enhancer-binding protein alpha (C/EBPalpha), a key regulator of energy homeostasis and cellular differentiation. A Lys(159) --> Arg substitution within the SC motif does not alter C/EBPalpha activity from a single site but leads to enhanced transactivation from synthetic or natural compound response elements. The sequence of SC motifs overlaps with the recently defined consensus SUMO modification site, and we find that the SC motif is the major site of both SUMO-1 and SUMO-3 modification in C/EBPalpha. Furthermore, the disruption of SC motif function is accompanied by loss of SUMO but not ubiquitin modification. C/EBPalpha interacts directly with the E2 SUMO-conjugating enzyme Ubc9 and can be SUMOylated in vitro using purified recombinant components. Notably, we find that PIASy has E3-like activity and enhances both SUMO-1 and SUMO-3 modification of C/EBPalpha in vivo and in vitro. Our results indicate that SUMO modification of SC motifs provides a means to rapidly control higher order interactions among transcription factors and suggests that SUMOylation may be a general mechanism to limit transcriptional synergy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12511558     DOI: 10.1074/jbc.M210440200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Direct and distinguishable inhibitory roles for SUMO isoforms in the control of transcriptional synergy.

Authors:  Sam Holmstrom; Mary E Van Antwerp; Jorge A Iñiguez-Lluhi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-08       Impact factor: 11.205

2.  Small ubiquitin-like modifier (SUMO) modification mediates function of the inhibitory domains of developmental regulators FOXC1 and FOXC2.

Authors:  Theodora E Danciu; Sergey Chupreta; Osvaldo Cruz; Jennifer E Fox; Malcolm Whitman; Jorge A Iñiguez-Lluhí
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

3.  A small conserved surface in SUMO is the critical structural determinant of its transcriptional inhibitory properties.

Authors:  Sergey Chupreta; Sam Holmstrom; Lalitha Subramanian; Jorge A Iñiguez-Lluhí
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

4.  SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5.

Authors:  Mark D Benson; Qiu-Ju Li; Katherine Kieckhafer; David Dudek; Matthew R Whorton; Roger K Sunahara; Jorge A Iñiguez-Lluhí; Jeffrey R Martens
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-29       Impact factor: 11.205

5.  An extended consensus motif enhances the specificity of substrate modification by SUMO.

Authors:  Shen-Hsi Yang; Alex Galanis; James Witty; Andrew D Sharrocks
Journal:  EMBO J       Date:  2006-10-12       Impact factor: 11.598

6.  PIASy-mediated sumoylation of SREBP1c regulates hepatic lipid metabolism upon fasting signaling.

Authors:  Gha Young Lee; Hagoon Jang; Jae Ho Lee; Jin Young Huh; Sekyu Choi; Jongkyeong Chung; Jae Bum Kim
Journal:  Mol Cell Biol       Date:  2013-12-30       Impact factor: 4.272

7.  Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors.

Authors:  Serge Grégoire; Xiang-Jiao Yang
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

8.  PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts.

Authors:  Tomohiro Hikata; Hironari Takaishi; Jiro Takito; Akihiro Hakozaki; Mitsuru Furukawa; Shinichi Uchikawa; Tokuhiro Kimura; Yasunori Okada; Masahito Matsumoto; Akihiko Yoshimura; Riko Nishimura; Sakamuri V Reddy; Hiroshi Asahara; Yoshiaki Toyama
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

9.  Comparison of TFII-I gene family members deleted in Williams-Beuren syndrome.

Authors:  Timothy A Hinsley; Pamela Cunliffe; Hannah J Tipney; Andrew Brass; May Tassabehji
Journal:  Protein Sci       Date:  2004-10       Impact factor: 6.725

10.  SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX.

Authors:  Sam R Holmstrom; Sergey Chupreta; Alex Yick-Lun So; Jorge A Iñiguez-Lluhí
Journal:  Mol Endocrinol       Date:  2008-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.